The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.
Jeffrey Alan Sosman
Research Funding - Novartis
Muaiad Kittaneh
Research Funding - Novartis
Martijn P. J. K. Lolkema
Honoraria - Novartis
Michael Andrew Postow
No relevant relationships to disclose
Gary Schwartz
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Catherine Franklin
Employment or Leadership Position - Novartis
Alessandro Matano
Employment or Leadership Position - Novartis
Suraj Bhansali
Employment or Leadership Position - Novartis
Sudha Parasuraman
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Kevin Kim
Research Funding - Novartis